Sanofi (NASDAQ:SNY) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp lowered its stake in shares of Sanofi (NASDAQ:SNY) by 0.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 561,036 shares of the company’s stock after selling 993 shares during the period. Van ECK Associates Corp’s holdings in Sanofi were worth $29,673,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of SNY. Manning & Napier Advisors LLC purchased a new stake in shares of Sanofi during the second quarter worth about $13,725,000. Mount Yale Investment Advisors LLC increased its stake in shares of Sanofi by 44.3% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after purchasing an additional 30,115 shares during the last quarter. Sei Investments Co. increased its stake in Sanofi by 9.3% during the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after acquiring an additional 47,297 shares during the last quarter. Finally, Atria Investments Inc lifted its position in Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after buying an additional 23,463 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of SNY opened at $52.95 on Tuesday. Sanofi has a one year low of $45.00 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market capitalization of $134.38 billion, a price-to-earnings ratio of 27.02, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61. The stock’s fifty day moving average is $55.85 and its 200-day moving average is $52.10.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company posted $2.55 EPS. Equities analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Argus lifted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.